Pathogenesis and emerging mast cell–targeted therapies in chronic inducible urticarias: a comprehensive review

Chronic inducible urticarias (CIndUs) are a clinically heterogeneous group of mast cell–driven disorders triggered by specific physical or environmental stimuli, resulting in recurrent wheals, angioedema, and pruritus that significantly impair health-related quality of life. Pathogenesis converges on aberrant mast-cell activation through both IgE-dependent and IgE-independent mechanisms, including signaling through the c-Kit receptor and Mas-related G protein–coupled receptor X2 (MRGPRX2), with key downstream effectors such as Bruton’s tyrosine kinase (BTK); contributions from basophils, neuroimmune crosstalk, and upregulated FcϵRI expression further amplify these responses. First-line therapy with second-generation H1-antihistamines, titrated up to four-fold, fails a substantial proportion of patients, and while omalizumab demonstrates meaningful efficacy, particularly in symptomatic dermographism (SD), cold urticaria (ColdU), and delayed pressure urticaria (DPU), responses vary markedly across subtypes and remain inferior to those observed in chronic spontaneous urticaria (CSU). Emerging mechanism-based therapies offer new avenues for refractory disease: next-generation anti-IgE antibodies, BTK inhibitors, MRGPRX2 antagonists, and c-Kit–directed biologics have demonstrated encouraging clinical activity, with anti-c-Kit strategies achieving particularly robust response rates by silencing or depleting the mast-cell compartment. Repurposed agents, including Siglec-8–directed antibodies, IL-5 pathway inhibitors, and doxycycline, may benefit select patients. This review synthesizes current evidence on CIndU pathogenesis and evaluates therapeutic strategies targeting its key pathogenic pathways, highlighting critical research gaps and the need for subtype-specific, adequately powered trials to enable personalized and more effective long-term disease management.

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2026-11-19
DOI
https://doi.org/10.3389/fimmu.2026.1907753
Primary Topic
Urticaria and Related Conditions
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Pathogenesis and emerging mast cell–targeted therapies in chronic inducible urticarias: a comprehensive review

Ferhan Saleem, Hermenio Lima, Karla Robles‐Velasco, Herberto José Chong Neto et al.
Frontiers in Immunology
Urticaria and Related Conditions
article

Pathogenesis and emerging mast cell–targeted therapies in chronic inducible urticarias: a comprehensive review

Ferhan Saleem, Hermenio Lima, Karla Robles‐Velasco, Herberto José Chong Neto, Danna Soria, Isabel Canzi Almada de Souza Lima, Iván Cherrez-Ojeda, Ryan Jackson, José Mendoza
article en

Abstract

Chronic inducible urticarias (CIndUs) are a clinically heterogeneous group of mast cell–driven disorders triggered by specific physical or environmental stimuli, resulting in recurrent wheals, angioedema, and pruritus that significantly impair health-related quality of life. Pathogenesis converges on aberrant mast-cell activation through both IgE-dependent and IgE-independent mechanisms, including signaling through the c-Kit receptor and Mas-related G protein–coupled receptor X2 (MRGPRX2), with key downstream effectors such as Bruton’s tyrosine kinase (BTK); contributions from basophils, neuroimmune crosstalk, and upregulated FcϵRI expression further amplify these responses. First-line therapy with second-generation H1-antihistamines, titrated up to four-fold, fails a substantial proportion of patients, and while omalizumab demonstrates meaningful efficacy, particularly in symptomatic dermographism (SD), cold urticaria (ColdU), and delayed pressure urticaria (DPU), responses vary markedly across subtypes and remain inferior to those observed in chronic spontaneous urticaria (CSU). Emerging mechanism-based therapies offer new avenues for refractory disease: next-generation anti-IgE antibodies, BTK inhibitors, MRGPRX2 antagonists, and c-Kit–directed biologics have demonstrated encouraging clinical activity, with anti-c-Kit strategies achieving particularly robust response rates by silencing or depleting the mast-cell compartment. Repurposed agents, including Siglec-8–directed antibodies, IL-5 pathway inhibitors, and doxycycline, may benefit select patients. This review synthesizes current evidence on CIndU pathogenesis and evaluates therapeutic strategies targeting its key pathogenic pathways, highlighting critical research gaps and the need for subtype-specific, adequately powered trials to enable personalized and more effective long-term disease management.

Frontiers in ImmunologyVol. 17
Brock University (CA), Universidad Espíritu Santo (EC), St. Martinus University (CW), Humboldt-Universität zu Berlin (DE), Fraunhofer Institute for Translational Medicine and Pharmacology (DE), Probity Medical Research (CA), Hospital de Clínicas Universidade Federal do Paraná (BR), Universidade Federal do Paraná (BR), Freie Universität Berlin (DE), Charité - Universitätsmedizin Berlin (DE)
Urticaria and Related Conditions
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon